Compare Divis Laboratories with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs CIPLA - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES CIPLA DIVIS LABORATORIES/
CIPLA
 
P/E (TTM) x 51.7 37.4 138.2% View Chart
P/BV x 11.9 4.1 290.2% View Chart
Dividend Yield % 0.5 0.4 130.8%  

Financials

 DIVIS LABORATORIES   CIPLA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-19
CIPLA
Mar-19
DIVIS LABORATORIES/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,639678 241.8%   
Low Rs1,115484 230.5%   
Sales per share (Unadj.) Rs186.3198.2 94.0%  
Earnings per share (Unadj.) Rs51.018.5 275.1%  
Cash flow per share (Unadj.) Rs57.335.0 163.8%  
Dividends per share (Unadj.) Rs16.003.00 533.3%  
Dividend yield (eoy) %1.20.5 225.0%  
Book value per share (Unadj.) Rs261.8186.3 140.5%  
Shares outstanding (eoy) m265.47805.70 32.9%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x7.42.9 252.2%   
Avg P/E ratio x27.031.4 86.2%  
P/CF ratio (eoy) x24.016.6 144.7%  
Price / Book Value ratio x5.33.1 168.7%  
Dividend payout %31.416.2 193.9%   
Avg Mkt Cap Rs m365,592468,031 78.1%   
No. of employees `00011.822.6 52.3%   
Total wages/salary Rs m5,42328,565 19.0%   
Avg. sales/employee Rs Th4,175.17,053.1 59.2%   
Avg. wages/employee Rs Th457.71,261.5 36.3%   
Avg. net profit/employee Rs Th1,141.8659.1 173.2%   
INCOME DATA
Net Sales Rs m49,463159,710 31.0%  
Other income Rs m1,5564,766 32.7%   
Total revenues Rs m51,019164,475 31.0%   
Gross profit Rs m18,71830,973 60.4%  
Depreciation Rs m1,68913,263 12.7%   
Interest Rs m351,684 2.1%   
Profit before tax Rs m18,55120,791 89.2%   
Minority Interest Rs m0-172 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,0235,695 88.2%   
Profit after tax Rs m13,52714,924 90.6%  
Gross profit margin %37.819.4 195.1%  
Effective tax rate %27.127.4 98.9%   
Net profit margin %27.39.3 292.7%  
BALANCE SHEET DATA
Current assets Rs m46,501124,266 37.4%   
Current liabilities Rs m8,46837,715 22.5%   
Net working cap to sales %76.954.2 141.9%  
Current ratio x5.53.3 166.7%  
Inventory Days Days13191 144.3%  
Debtors Days Days8695 90.5%  
Net fixed assets Rs m25,797105,190 24.5%   
Share capital Rs m5311,611 32.9%   
"Free" reserves Rs m68,962148,511 46.4%   
Net worth Rs m69,493150,123 46.3%   
Long term debt Rs m038,301 0.0%   
Total assets Rs m80,383239,633 33.5%  
Interest coverage x531.013.3 3,979.4%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.60.7 92.3%   
Return on assets %16.96.9 243.4%  
Return on equity %19.59.9 195.8%  
Return on capital %26.711.8 225.9%  
Exports to sales %034.7 0.0%   
Imports to sales %24.60-   
Exports (fob) Rs mNA55,419 0.0%   
Imports (cif) Rs m12,187NA-   
Fx inflow Rs m41,23857,410 71.8%   
Fx outflow Rs m12,40519,041 65.1%   
Net fx Rs m28,83338,368 75.1%   
CASH FLOW
From Operations Rs m9,54316,911 56.4%  
From Investments Rs m-6,854-16,687 41.1%  
From Financial Activity Rs m-2,459-3,487 70.5%  
Net Cashflow Rs m230-3,451 -6.7%  

Share Holding

Indian Promoters % 52.0 16.0 325.0%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 11.8 12.2 96.7%  
FIIs % 19.0 23.7 80.2%  
ADR/GDR % 0.0 1.1 -  
Free float % 17.2 26.2 65.6%  
Shareholders   31,796 161,166 19.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   ALKEM LABORATORIES  FRESENIUS KABI ONCO.  FDC.  TORRENT PHARMA  STRIDES PHARMA SCIENCE  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Lower Tracking Weak Global Cues; L&T Slips 4% Post Q2 Results(09:30 am)

Asian share markets are trading on a negative note today. The Nikkei is trading down by 0.7% and the Hang Seng is trading lower by 1%.

Related Views on News

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)

May 19, 2020 | Updated on May 19, 2020

For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY20); Net Profit Down 4.9% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 4.9% YoY). Sales on the other hand came in at Rs 14 bn (up 3.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

My View on ITC(Fast Profits Daily)

Oct 23, 2020

What do the charts say about ITC?

PSU Banks Will Move Up Again(Profit Hunter)

Oct 27, 2020

My charts tell me PSU banks are set for a rebound.

One of the Best Investment Opportunities in the Market Right Now(Fast Profits Daily)

Oct 16, 2020

The one sector that you should be looking at to make good profits.

Why India's Drone Revolution is a 4x Profit Opportunity(Profit Hunter)

Oct 16, 2020

My research on India's leading defence companies brought me to one major player in drone manufacturing.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Oct 29, 2020 09:48 AM

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 5-YR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS